AQP4 and neuromyelitis optica: The Panel recommends testing for AQP4 autoantibodies with validated assays in patients who are suspected of having NMO or NMO spectrum disorders, especially in patients with Asian or Latin American genetic background because of the higher prevalence of the disease in these populations.